Abstract: The Kirsten rat sarcoma viral oncogene homolog (KRAS) is a highly prevalent driver of oncogenesis in solid tumors, historically deemed "undruggable." Recent advancements have led to the development of mutant-specific inhibitors, but the need for broader therapeutic strategies has driven the discovery of pan-KRAS inhibitors. BI-2865, developed by Boehringer Ingelheim, is a novel, non-covalent pan-KRAS inhibitor that targets the inactive state of the KRAS protein. It demonstrates remarkable selectivity for KRAS over other RAS isoforms (HRAS and NRAS) and exhibits potent inhibitory activity against a wide array of common KRAS mutations, including G12, G13, and Q61H variants. By binding to the switch-II pocket, BI-2865 effectively reduces tumor proliferation in both cell lines and preclinical mouse models. However, its pan-KRAS activity also results in the inactivation of wild-type KRAS, raising questions about potential clinical toxicity. Furthermore, shared binding modalities with other switch-II pocket inhibitors suggest a susceptibility to emerging secondary resistance mutations. This review synthesizes the pharmacological profile, molecular mechanism, structure-activity relationships, limitations, and future perspectives of BI-2865 as a pan-KRAS targeted therapy.
1. Introduction
The Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most frequently mutated oncogene in human cancers, with mutations in the RAS family affecting approximately 30% of all cancer diagnoses [1]. For decades, KRAS was considered an "undruggable" target due to its lack of deep pharmacological binding pockets and its high affinity for intracellular GTP. However, the landscape of RAS-targeted therapy was revolutionized by the discovery of the allosteric switch-II pocket, which led to the development and FDA approval of the first covalent inhibitors targeting the specific KRAS G12C mutation (such as Sotorasib and Adagrasib) [1].
Despite these breakthroughs, G12C-specific inhibitors are ineffective against other highly prevalent oncogenic variants, such as G12D, G12V, and G13D, which drive a significant proportion of colorectal, lung, and pancreatic ductal adenocarcinomas [1]. To address this critical gap, drug discovery efforts have expanded toward pan-KRAS inhibitors capable of targeting multiple mutant forms simultaneously. Among these next-generation therapeutics is BI-2865, a non-covalent pan-KRAS inhibitor developed by Boehringer Ingelheim. BI-2865 represents a significant structural and pharmacological milestone in the direct drugging of RAS, offering a broad-spectrum approach to KRAS-driven solid tumors [1].
2. Pharmacological Activity
BI-2865 is a highly potent, non-covalent inhibitor that demonstrates broad activity across multiple KRAS mutations. In preclinical evaluations, BI-2865 successfully reduced tumor proliferation in both cancer cell lines and mouse models [1]. The compound exhibits strong binding affinities (Kd) across a spectrum of KRAS variants, including:
- KRAS G13D: 4.3 nM
- KRAS G12C: 4.5 nM
- KRAS WT (Wild-Type): 6.9 nM
- KRAS G12V: 26 nM
- KRAS G12D: 32 nM
The inhibitor is effective against many common G12, G13, and Q61H mutations. However, it does not inhibit the G12R mutation or other specific Q61 mutations [1]. A defining pharmacological feature of BI-2865 is its exceptional isoform selectivity; it is approximately two to three orders of magnitude more selective for KRAS than for the closely related HRAS and NRAS isoforms [1].
3. Molecular Mechanism of Action
The molecular mechanism of BI-2865 involves the non-covalent targeting of the inactive, GDP-bound state of the KRAS protein [1]. Like the early G12C-specific inhibitors (Adagrasib and Sotorasib) and the non-covalent G12D inhibitor MRTX-1133, BI-2865 binds to the allosteric switch-II pocket of KRAS [1]. By occupying this pocket, BI-2865 stabilizes the inactive conformation of the protein, thereby disabling oncogenic signaling pathways that rely on the active, GTP-bound state of KRAS to promote tumor growth and proliferation [1].
4. Structure-Activity Relationship (SAR)
The design of BI-2865 was heavily informed by G12C pharmacophores that target the inactive form of KRAS, supported by atomic-resolution crystal structures [1]. The crystal structure of KRAS G12C in complex with BI-2865 (PDB: 8AZR) reveals a binding mode in the switch-II pocket that is highly similar to that of Adagrasib and MRTX-1133 [1].
Based on structural complex analyses and mutagenesis studies, the remarkable selectivity of BI-2865 for KRAS over HRAS and NRAS is primarily conferred by interactions around the H95 residue. Histidine 95 (H95) is one of the few amino acids within the RAS G-domain that differs among the various RAS isoforms, providing a critical structural basis for isoform-specific drug design [1]. Furthermore, structural data indicate that residues R68, H95, Y96, and Q99 within the switch-II pocket make crucial contacts with BI-2865, stabilizing the drug-protein interaction [1].
5. Current Limitations
Despite its promising preclinical profile, the development of BI-2865 faces several notable limitations:
Wild-Type KRAS Inhibition: As a pan-KRAS inhibitor, BI-2865 binds to and inactivates wild-type (WT) KRAS with a high affinity (Kd = 6.9 nM) [1]. Currently, there is a lack of clinical data demonstrating the physiological consequences and potential toxicities associated with systemic WT KRAS blockade in human patients. While it is hypothesized that WT KRAS activity might be functionally compensated by the uninhibited NRAS and HRAS isoforms, the tolerability of this pan-KRAS inhibition remains a significant clinical question [1].
Acquired Resistance and Secondary Mutations: Because BI-2865 shares a very similar switch-II binding mode with other inhibitors like Adagrasib and MRTX-1133, it is highly susceptible to acquired resistance via secondary point mutations. Residues that make crucial contacts with BI-2865—specifically R68, H95, Y96, and Q99—have already been identified as sites of secondary mutations in patients treated with G12C inhibitors. Alterations at these sites can disrupt critical hydrogen bonds or hydrophobic interactions, potentially rendering BI-2865 ineffective [1].
Mutation-Specific Gaps: While broad in its activity, BI-2865 fails to inhibit the G12R mutation and certain Q61 mutations, leaving a subset of KRAS-driven tumors without coverage by this specific agent [1].
6. Future Perspectives
The advent of pan-KRAS inhibitors like BI-2865 marks a significant leap forward in the treatment of RAS-driven solid tumors, moving the field beyond allele-specific limitations. Moving forward, the transition of BI-2865 into clinical trials will be critical to ascertain how well patients tolerate the concurrent inhibition of mutant and wild-type KRAS [1].
To combat the inevitable emergence of acquired resistance via secondary switch-II mutations, future therapeutic strategies will likely require combination regimens. Combining BI-2865 with upstream receptor tyrosine kinase (RTK) inhibitors, downstream effector pathway inhibitors, or novel immunotherapies could help circumvent resistance mechanisms and enhance overall clinical efficacy [1]. Additionally, the structural insights gained from the BI-2865 binding mode, particularly its exploitation of the H95 residue for isoform selectivity, will continue to guide the rational design of next-generation RAS inhibitors [1].
